Redwood City, Calif.-based startup Heartflow Inc. has received a new technology ambulatory payment classification (APC) for its FFRct Analysis. This is an FDA-cleared, novel, noninvasive, coronary artery disease diagnostic that pairs deep learning with a conventional CT angiogram to create a digital 3-D model of the patient's coronary arteries. The Centers for Medicare and Medicaid Services (CMS) classification will make it easier to achieve reimbursement for FFRct, which is already partnered with Siemens Healthineers, GE Healthcare and Royal Philips. (See BioWorld Medtech, Aug. 30, 2017.)